Brief: Allergy Therapeutics Screening For Grass MATA MPL to Complete By Early Q1 2026
30/10/2025 07:21
Oct 30 (Reuters) - Allergy Therapeutics PLC AGY.L: ALLERGY THERAPEUTICS - G308 PHASE III YEAR 2 PATIENT SCREENING STARTS ALLERGY THERAPEUTICS PLC - SCREENING FOR GRASS MATA MPL TO COMPLETE BY EARLY Q1 2026 ALLERGY THERAPEUTICS PLC - SHORT-TERM SAFETY DATA EXPECTED IN Q4 2025 Source text: ID:nRSd4066Fa Further company coverage: AGY.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allergy Therapeutics
See all newsRCS - Allergy Therapeutics - Allergy Therapeutics to present at EAACI 2026
UK's Allergy Therapeutics H1 revenue rises 7%, operating loss widens
Brief: Allergy Therapeutics H1 Pretax Profit GBP -19.33 Million
Allergy Therapeutics - Interim Results for six months ended 31 Dec 2025
Allergy Therapeutics - PDMR Dealings & Shareholding Update